Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

MRI Predictors of Recurrence and Outcome after Acute Transverse Myelitis of Unidentified Etiology.

Bulut E, Shoemaker T, Karakaya J, Ray DM, Mealy MA, Levy M, Izbudak I.

AJNR Am J Neuroradiol. 2019 Jul 11. doi: 10.3174/ajnr.A6121. [Epub ahead of print]

PMID:
31296526
2.

A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder.

Mealy MA, Levy M.

Medicine (Baltimore). 2019 Jun;98(25):e15944. doi: 10.1097/MD.0000000000015944.

3.

Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D.

Mealy MA, Boscoe A, Caro J, Levy M.

Int J MS Care. 2019 May-Jun;21(3):129-134. doi: 10.7224/1537-2073.2017-076.

4.

Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder.

Mealy MA, Kozachik SL, Levy M.

Pain Manag Nurs. 2019 May 15. pii: S1524-9042(18)30407-7. doi: 10.1016/j.pmn.2019.03.003. [Epub ahead of print] Review.

PMID:
31103517
5.

Case Report: Scrambler Therapy for Treatment-Resistant Central Neuropathic Pain in a Patient with Transverse Myelitis.

Mealy MA, Newsome SD, Kozachik SL, Levy M, Smith TJ.

Int J MS Care. 2019 Mar-Apr;21(2):76-80. doi: 10.7224/1537-2073.2017-083.

6.

Updated diagnostic criteria for neuromyelitis optica spectrum disorder: Similar outcomes of previously separate cohorts.

McCreary M, Mealy MA, Wingerchuk DM, Levy M, DeSena A, Greenberg BM.

Mult Scler J Exp Transl Clin. 2018 Dec 6;4(4):2055217318815925. doi: 10.1177/2055217318815925. eCollection 2018 Oct-Dec.

7.

Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.

Mealy MA, Mossburg SE, Kim SH, Messina S, Borisow N, Lopez-Gonzalez R, Ospina JP, Scheel M, Yeshokumar AK, Awad A, Leite MI, Arango JJ, Paul F, Palace J, Kim HJ, Levy M.

Mult Scler Relat Disord. 2019 Feb;28:64-68. doi: 10.1016/j.msard.2018.12.011. Epub 2018 Dec 9.

PMID:
30554040
8.

Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment.

Banerjee A, Ng J, Coleman J, Ospina JP, Mealy M, Levy M.

Mult Scler Relat Disord. 2019 Feb;28:60-63. doi: 10.1016/j.msard.2018.12.010. Epub 2018 Dec 10.

PMID:
30554039
9.

Racial differences in neuromyelitis optica spectrum disorder.

Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, Han M, Leite MI, Palace J, Kim HJ.

Neurology. 2018 Nov 27;91(22):e2089-e2099. doi: 10.1212/WNL.0000000000006574. Epub 2018 Oct 26.

PMID:
30366977
10.

MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.

Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, Paul F, Levy M.

Mult Scler Relat Disord. 2018 Oct;25:66-72. doi: 10.1016/j.msard.2018.07.025. Epub 2018 Jul 24. Review.

PMID:
30048919
11.

Mortality in neuromyelitis optica is strongly associated with African ancestry.

Mealy MA, Kessler RA, Rimler Z, Reid A, Totonis L, Cutter G, Kister I, Levy M.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 7;5(4):e468. doi: 10.1212/NXI.0000000000000468. eCollection 2018 Jul. No abstract available.

12.

Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder.

Mealy MA, Cook LJ, Pache F, Velez DL, Borisow N, Becker D, Arango JAJ, Paul F, Levy M.

Mult Scler Relat Disord. 2018 Jul;23:78-82. doi: 10.1016/j.msard.2018.05.003. Epub 2018 May 7.

PMID:
29783157
13.

Familial monophasic acute transverse myelitis due to the pathogenic variant in VPS37A.

Mealy MA, Nam TS, Pardo SJ, Pardo CA, Sobreira NL, Avramopoulos D, Valle D, Burns KH, Levy M.

Neurol Genet. 2018 Jan 30;4(1):e213. doi: 10.1212/NXG.0000000000000213. eCollection 2018 Feb.

14.

Scrambler Therapy for the Treatment of Chronic Central Pain: A Case Report.

D'Amato SJ, Mealy MA, Erdek MA, Kozachik S, Smith TJ.

A A Pract. 2018 Jun 15;10(12):313-315. doi: 10.1213/XAA.0000000000000695.

PMID:
29293482
15.

Two-year observational study of deferiprone in superficial siderosis.

Kessler RA, Li X, Schwartz K, Huang H, Mealy MA, Levy M.

CNS Neurosci Ther. 2018 Mar;24(3):187-192. doi: 10.1111/cns.12792. Epub 2017 Dec 28.

16.

Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis.

Schwartz K, Wymbs NF, Huang H, Mealy MA, Pardo CA, Zackowski K, Levy M.

Mult Scler J Exp Transl Clin. 2017 Nov 8;3(4):2055217317740145. doi: 10.1177/2055217317740145. eCollection 2017 Oct-Dec.

17.

Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy.

Barreras P, Fitzgerald KC, Mealy MA, Jimenez JA, Becker D, Newsome SD, Levy M, Gailloud P, Pardo CA.

Neurology. 2018 Jan 2;90(1):e12-e21. doi: 10.1212/WNL.0000000000004765. Epub 2017 Dec 1.

18.

High risk of postpartum relapses in neuromyelitis optica spectrum disorder.

Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B.

Neurology. 2017 Nov 28;89(22):2238-2244. doi: 10.1212/WNL.0000000000004681. Epub 2017 Nov 1.

19.

Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.

Kessler RA, Mealy MA, Jimenez-Arango JA, Quan C, Paul F, López R, Hopkins S, Levy M.

Mult Scler Relat Disord. 2017 Oct;17:198-201. doi: 10.1016/j.msard.2017.08.005. Epub 2017 Aug 16.

PMID:
29055457
20.

Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community.

Eaneff S, Wang V, Hanger M, Levy M, Mealy MA, Brandt AU, Eek D, Ratchford JN, Nyberg F, Goodall J, Wicks P.

Mult Scler Relat Disord. 2017 Oct;17:116-122. doi: 10.1016/j.msard.2017.07.014. Epub 2017 Jul 11.

21.

Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.

Abboud H, Rossman I, Mealy MA, Hill E, Thompson N, Banerjee A, Probasco J, Levy M.

J Neurol. 2017 Nov;264(11):2284-2292. doi: 10.1007/s00415-017-8627-4. Epub 2017 Oct 3.

PMID:
28975404
22.

Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.

Mealy MA, Kim SH, Schmidt F, López R, Jimenez Arango JA, Paul F, Wingerchuk DM, Greenberg BM, Kim HJ, Levy M.

Mult Scler. 2018 Nov;24(13):1737-1742. doi: 10.1177/1352458517730131. Epub 2017 Aug 31.

PMID:
28857723
23.

Chiari I malformation in children with transverse myelitis.

Vadivelu S, Vadivelu S, Mealy M, Patel S, Kosnik-Infinger L, Becker D.

Dev Neurorehabil. 2018 Aug;21(6):402-407. doi: 10.1080/17518423.2017.1323972. Epub 2017 May 24.

PMID:
28537458
24.

Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study.

Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 24;4(3):e339. doi: 10.1212/NXI.0000000000000339. eCollection 2017 May.

25.

Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders.

Orman G, Wang KY, Pekcevik Y, Thompson CB, Mealy M, Levy M, Izbudak I.

AJNR Am J Neuroradiol. 2017 May;38(5):949-953. doi: 10.3174/ajnr.A5141. Epub 2017 Mar 16.

26.

TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders.

Barreras P, Mealy MA, Pardo CA.

J Neurol Sci. 2017 Feb 15;373:303-306. doi: 10.1016/j.jns.2017.01.023. Epub 2017 Jan 7.

PMID:
28131210
27.

Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder.

Chavarro VS, Mealy MA, Simpson A, Lacheta A, Pache F, Ruprecht K, Gold SM, Paul F, Brandt AU, Levy M.

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 24;3(6):e286. eCollection 2016 Dec.

28.

Using PAT to accelerate the transition to continuous API manufacturing.

Gouveia FF, Rahbek JP, Mortensen AR, Pedersen MT, Felizardo PM, Bro R, Mealy MJ.

Anal Bioanal Chem. 2017 Jan;409(3):821-832. doi: 10.1007/s00216-016-9834-z. Epub 2016 Aug 11.

PMID:
27515798
29.

Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder.

Kessler RA, Mealy MA, Levy M.

Neurol Neuroimmunol Neuroinflamm. 2016 Jul 28;3(5):e269. doi: 10.1212/NXI.0000000000000269. eCollection 2016 Oct.

30.

Cognition, mood, and purpose in life in neuromyelitis optica spectrum disorder.

Hollinger KR, Franke C, Arenivas A, Woods SR, Mealy MA, Levy M, Kaplin AI.

J Neurol Sci. 2016 Mar 15;362:85-90. doi: 10.1016/j.jns.2016.01.010. Epub 2016 Jan 11. No abstract available.

PMID:
26944124
31.

Spinal Movement Disorders in Neuromyelitis Optica: An Under-recognized Phenomenon.

Abboud H, Fernandez HH, Mealy MA, Levy M.

Mov Disord Clin Pract. 2016 Feb 11;3(6):596-602. doi: 10.1002/mdc3.12321. eCollection 2016 Nov-Dec.

32.

Bevacizumab is safe in acute relapses of neuromyelitis optica.

Mealy MA, Shin K, John G, Levy M.

Clin Exp Neuroimmunol. 2015 Nov 1;6(4):413-418. Epub 2015 Aug 24.

33.

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.

Kessler RA, Mealy MA, Levy M.

Curr Treat Options Neurol. 2016 Jan;18(1):2. doi: 10.1007/s11940-015-0387-9.

34.

What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Pekcevik Y, Orman G, Lee IH, Mealy MA, Levy M, Izbudak I.

Clin Imaging. 2016 May-Jun;40(3):573-80. doi: 10.1016/j.clinimag.2015.07.027. Epub 2015 Jul 26. Review.

35.
36.

Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.

Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD, Thompson CB, Pardo CA, Calabresi PA, Levy M, Izbudak I.

Mult Scler. 2016 Mar;22(3):302-11. doi: 10.1177/1352458515591069. Epub 2015 Jul 24.

37.

Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis.

Mealy MA, Whetstone A, Orman G, Izbudak I, Calabresi PA, Levy M.

J Neurol Sci. 2015 Aug 15;355(1-2):59-63. doi: 10.1016/j.jns.2015.05.013. Epub 2015 May 17.

38.

Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.

Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M.

Mult Scler. 2016 Feb;22(2):185-92. doi: 10.1177/1352458515581438. Epub 2015 Apr 28.

39.

Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica.

Levy M, Mealy MA.

Neurol Neuroimmunol Neuroinflamm. 2014 Apr 24;1(1):e5. doi: 10.1212/NXI.0000000000000005. eCollection 2014 Jun.

40.

Predictors of recurrence following an initial episode of transverse myelitis.

Kimbrough DJ, Mealy MA, Simpson A, Levy M.

Neurol Neuroimmunol Neuroinflamm. 2014 Apr 24;1(1):e4. doi: 10.1212/NXI.0000000000000004. eCollection 2014 Jun.

41.

Asymmetric intramolecular carbolithiation of achiral substrates: synthesis of enantioenriched (R)-(+)-cuparene and (R)-(+)-herbertene.

Luderer MR, Mealy MJ, Bailey WF.

J Org Chem. 2014 Nov 7;79(21):10722-6. doi: 10.1021/jo502139m. Epub 2014 Oct 23.

PMID:
25303318
42.

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.

Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M.

JAMA Neurol. 2014 Mar;71(3):324-30. doi: 10.1001/jamaneurol.2013.5699.

PMID:
24445513
43.

Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients.

Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L, Mutch K, Levy M, Takai Y, Collongues N, Banwell B, Fujihara K, de Seze J.

Mult Scler. 2014 Jun;20(7):843-7. doi: 10.1177/1352458513507822. Epub 2013 Oct 7.

PMID:
24099751
44.

In vivo identification of morphologic retinal abnormalities in neuromyelitis optica.

Sotirchos ES, Saidha S, Byraiah G, Mealy MA, Ibrahim MA, Sepah YJ, Newsome SD, Ratchford JN, Frohman EM, Balcer LJ, Crainiceanu CM, Nguyen QD, Levy M, Calabresi PA.

Neurology. 2013 Apr 9;80(15):1406-14. doi: 10.1212/WNL.0b013e31828c2f7a. Epub 2013 Mar 20.

45.

What is the true clinicopathologic spectrum of neuromyelitis optica?-Reply.

Greenberg BM, Wingerchuk D, Mealy M, Levy M.

JAMA Neurol. 2013 Feb;70(2):272-3. doi: 10.1001/jamaneurol.2013.1286. No abstract available.

PMID:
23400728
46.

Epidemiology of neuromyelitis optica in the United States: a multicenter analysis.

Mealy MA, Wingerchuk DM, Greenberg BM, Levy M.

Arch Neurol. 2012 Sep;69(9):1176-80. doi: 10.1001/archneurol.2012.314.

PMID:
22733096
47.

Low serum vitamin D levels and recurrent inflammatory spinal cord disease.

Mealy MA, Newsome S, Greenberg BM, Wingerchuk D, Calabresi P, Levy M.

Arch Neurol. 2012 Mar;69(3):352-6. doi: 10.1001/archneurol.2011.1974. Epub 2011 Nov 14.

PMID:
22083799
48.

Effect of ligand structure on the asymmetric cyclization of achiral olefinic organolithiums.

Mealy MJ, Luderer MR, Bailey WF, Sommer MB.

J Org Chem. 2004 Sep 3;69(18):6042-9.

PMID:
15373489
50.

Impact of a computer-based auto-tutorial program on parasitology test scores of four consecutive classes of veterinary medical students.

Pinckney RD, Mealy MJ, Thomas CB, MacWilliams PS.

J Vet Med Educ. 2001 Winter;28(3):136-9.

PMID:
11721238

Supplemental Content

Support Center